Process optimisation for biologics is obligatory for efficient processing and reduction of Cost of Goods (COGs). Especially in the development of biosimilar antibodies, low COGs to manufacture the antibody provides a competitive advantage compared to competing biosimilar developers.
Metabolic control of CHOBC® for production of biologics
- Published:
- written by: Polpharma Biologics
Related news
Other news related to this topic that may be of interest to you
Bioeq and Zydus partners for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA
December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG,...
Polpharma Biologics and Libbs Farmacêutica sign licensing agreement for a biosimilar for autoimmune diseases
December 10, 2025 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development...
Polpharma Biologics confirms U.S. launch of Tyruko® (natalizumab), the first and only biosimilar for Multiple Sclerosis
November 17, 2025 – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development...
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar
Zurich, Switzerland – October 21, 2025 – Polpharma Biologics today announced Ranivisio® PFS (ranibizumab...